TNFAIP3 curbs lactylation-driven DNA repair and boosts chemotherapy sensitivity in ovarian cancer

Ovarian cancer remains one of the most lethal gynecologic malignancies, largely because tumors display extensive metabolic plasticity and rapidly develop resistance to platinum chemotherapy. A new open-access study published in Cellular Oncology points to a possible reason why: a lactate-derived chemical modification of proteins called lactylation appears to help ovarian cancer cells survive treatment, and a tumor suppressor gene named TNFAIP3 may counteract that process. The work, based on bulk transcriptomic analysis, single-cell RNA sequencing, machine learning, clinical validation and laboratory experiments, was published on 14 October 2026 as a peer-reviewed accepted manuscript carrying a permanent DOI.

The researchers first showed that global pan-Kla signals, a readout of lactylation across many proteins, were significantly elevated in ovarian cancer and correlated with advanced stage, metastasis, chemoresistance and poor prognosis. Single-cell analysis then identified two distinct lactylation-associated epithelial states within tumors, labeled PFKP-C1 and CBX3-C2, which the authors describe as metabolically adaptive and immune-interactive tumor programs, respectively. An exploratory prognostic model built from lactylation-related genes was associated with differences in survival and in the heterogeneity of the immune microenvironment, though the authors frame this model as exploratory rather than a validated clinical tool.

Among candidate genes from this screen, TNFAIP3 stood out as a functionally relevant tumor suppressor. It was markedly downregulated in ovarian cancer, particularly in chemoresistant tumors, and high TNFAIP3 expression predicted favorable survival in the clinical datasets examined. Functionally, the team showed that TNFAIP3 inhibited tumor progression while enhancing sensitivity to two drugs in laboratory cell assays: cisplatin, a standard platinum chemotherapy, and olaparib, a PARP inhibitor. In xenograft mouse models, TNFAIP3 potentiated the efficacy of cisplatin in vivo. These are preclinical and observational findings, so they do not yet establish a new treatment for patients.

The mechanistic story centers on how TNFAIP3 restrains a metabolic loop that supports DNA damage repair. According to the study, TNFAIP3 constrained LDHA-mediated lactate production, the enzymatic step that generates the lactate feeding lactylation. With less lactylation pressure, NBS1-associated lactylation was reduced, and the researchers observed attenuated DNA damage repair signaling. The authors further implicate HDAC3, a histone deacetylase, as a functional mediator of the TNFAIP3-associated removal of lactylation marks from NBS1.

The clinical implications are cautious but concrete. If TNFAIP3 levels or its downstream lactylation targets can be measured reliably, they could eventually help identify patients whose tumors are more likely to resist platinum therapy, and the lactylation pathway itself is presented by the authors as a potential direction for further therapeutic investigation rather than an established target. The study’s methods combined public datasets with immunoblotting, immunohistochemistry and multiplex immunofluorescence to assess TNFAIP3 expression and lactylation levels, and functional assays plus xenograft models to test the gene’s role in progression and chemoresistance. As with any early-stage cancer biology study, the findings require independent validation before they can inform screening or treatment decisions, and the published version remains subject to final editorial updates as the Version of Record replaces the accepted manuscript.

Subject of Research: The role of the tumor suppressor TNFAIP3 in regulating lactylation-associated DNA damage repair and chemosensitivity in ovarian cancer.

Article Title: TNFAIP3 suppresses lactylation-associated DNA damage repair and enhances chemosensitivity in ovarian cancer

Article References: Huang, H., Xu, L., Cheng, X., & Li, H. (2026). TNFAIP3 suppresses lactylation-associated DNA damage repair and enhances chemosensitivity in ovarian cancer. Cellular Oncology. https://doi.org/10.1007/s13402-026-01307-1

Image Credits: AI Generated

DOI: 10.1007/s13402-026-01307-1

Keywords: ovarian cancer, TNFAIP3, lactylation, DNA damage repair, chemoresistance, cisplatin, olaparib, LDHA, NBS1, HDAC3, tumor metabolism, single-cell RNA sequencing